Skip to main content

Table 4 Toxicity scenarios for PF03084014 in combination with doxorubicin

From: A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials

 

PF03084014

doxorubicin

1

2

3

2

0.22

0.33

0.67

1

0.08

0.13

0.36